NCT07554560Recruiting
Nutrition Intervention for Pancreatic Cancer
Feasibility, Tolerance, and Fat Metabolism Pilot Study of a Structured Lipid Medical Food in Patients With Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
Patients with pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (NET)) commonly experience fat malabsorption due to exocrine pancreatic insufficiency (EPI) and leads to gastrointestinal (GI) symptoms, malnutrition, weight loss, and reduced quality of life (QoL). Current standard treatment, pancreatic enzyme replacement therapy (PERT), is limited by suboptimal adherence, high cost, and partial effectiveness to prevent fat malabsorption. The objective of the study is to assess the feasibility and maintenance of lipid absorption function of a structured lipid medical food (SLMF; Encala®) powder in subjects with PDAC and NET with EPI.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 17 Apr 2026
- Start date
- 7 Apr 2026
- Primary completion date
- Apr 2027
- Lead sponsor
- Children's Hospital of Philadelphia
- Diseases
- Neuroendocrine tumours, Pancreatic cancer
- NCT number
- NCT07554560
What you commit to
- Study type: Interventional
- Planned participants: 18
- From 7 Apr 2026 to the primary completion date, Apr 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergy to soy lecithin product ingredients
Other
- Pregnant or lactating
- Unable to consume food by mouth (oral intake)
- Psychosocial environment for which study participation may be difficult for subject or family, as confirmed by medical team
- Military service members, Reserve Service members, National Guard members, Department of Defense (DoD) civilians, and DoD contractors
- Patients with diminished capacity to consent
Who the study is looking for
- Pancreatic ductal adenocarcinoma or pancreatic neuroendocrine tumor diagnosis and age greater than or equal to 18 years
- Life expectancy of 4 months or greater
- Oral or enteral tube feeding for \> 60% daily calories
- For patients with NET, evidence of GI dysfunction such as \>5% unintentional weight loss, increased number of bowel movements¸change in stool consistency (e.g., soft stool or diarrhea), as documented in the medical record and confirmed by the treating oncologist.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's Hospital of Philadelphia Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
| University of Pennsylvania/Abramson Cancer Center Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.